Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

An Open Label Extension Study of Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

This Open Label Extension study will enable eligible patients with Paroxysmal Supraventricular Tachycardia (PSVT) who have previously participated in a Milestone Pharmaceuticals clinical trial of etripamil NS for PSVT, to access continued treatment with etripamil NS, Patients who experienced any significant safety issues during participation period in a previous clinical trial of etripamil NS, as per Investigator's assessment , are excluded. This study will be conducted by Investigators who previously participated in a Milestone Pharmaceuticals clinical trial and are trained on the use of etripamil NS.

Study Overview

• Status: Completed
• Conditions: Paroxysmal Supraventricular Tachycardia
• Intervention / Treatment: Drug: Etripamil NS 70 mg; Device: Aptar Pharma Nasal Spray Bidose System

Detailed Description

Etripamil NS addresses an unmet medical need since there are currently no fast-acting products available for patient self-administered treatment of episodes of PSVT. The only currently available acute pharmacological therapy is IV treatment with adenosine or calcium channel blockers administered in a hospital or medically supervised environment. A self-administered product for PSVT would give patients the option to safely terminate acute episodes of PSVT without the need for a hospital visit and potential admission. An episodic treatment option may also allow selected patients to discontinue chronic prophylactic therapy with Class I, II (e.g., beta-blockers), III, and/or IV (e.g., calcium channel blockers) antiarrhythmic agents, thus avoiding the side effects and quality of life implications associated with these medications. Furthermore, patients weighing the risks of bridging therapy and an invasive catheter ablation procedure to address their PSVT would have the opportunity to consider episodic management with etripamil NS as a viable alternative treatment option.

The potential risks of study participation include those associated with exposure to etripamil NS. The side effect profile appears to be consistent with its expected pharmacology as a short-acting structural analog of verapamil, as well as with its delivery as moderately low pH nasal spray formulation. The most frequently reported (≥5% of subjects across all studies) AEs determined by the investigator to be possibly, probably, or definitely related to etripamil NS include headache, increased lacrimation, epistaxis, nasal congestion, nasal discomfort, rhinorrhea, sneezing and throat irritation.

Potential AEs, which have been rare or not observed in studies to date, include other cardiac arrhythmias, or AEs associated with drops in blood pressure (syncope, symptomatic hypotension).

The primary benefit of this study is that patients may be able to safely and rapidly terminate acute episodes of PSVT without the need for a hospital visit to receive IV medication. Patients may also be able to discontinue chronic prophylactic therapies they are taking for PSVT. Patients who are waiting for, ineligible, or unwilling to undergo ablation procedures may have an option for at-home treatment of their PSVT episodes.

• Study Type: Interventional
• Enrollment (Actual): 130
• Phase: Phase 3

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Victoria, British Columbia, Canada, V8T 1Z4
      • Site # 0213
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3H 3A7
      • Site # 0210
  • Ontario
    • Oshawa, Ontario, Canada, L1J 2K1
      • Site # 2006
    • Toronto, Ontario, Canada, M5B 1W8
      • Site # 0204
  • Quebec
    • Montreal, Quebec, Canada, H2X 0A9
      • Site # 0205
    • Montreal, Quebec, Canada, H1T 1C8
      • Site # 0203
• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72205
      • Site # 0160
  • California
    • Vista, California, United States, 92083
      • Site # 1023
    • West Hills, California, United States, 91307
      • Site # 1083
  • Georgia
    • Atlanta, Georgia, United States, 30309
      • Site # 0102
    • Macon, Georgia, United States, 31201
      • Site # 0137
  • Idaho
    • Coeur d'Alene, Idaho, United States, 83814
      • Site # 1115
  • Indiana
    • Fort Wayne, Indiana, United States, 46845
      • Site # 0149
  • Iowa
    • West Des Moines, Iowa, United States, 50266
      • Site # 1025
  • Maryland
    • Salisbury, Maryland, United States, 21801
      • Site # 1007
  • Michigan
    • Lansing, Michigan, United States, 48912
      • Site # 0166
  • New York
    • New York, New York, United States, 10065
      • Site # 0114
  • Ohio
    • Canton, Ohio, United States, 44710
      • Site # 1024
    • Toledo, Ohio, United States, 43606-
      • Site # 0110
  • Oregon
    • Corvallis, Oregon, United States, 97330
      • Site # 1123
  • Pennsylvania
    • Yardley, Pennsylvania, United States, 19067
      • Site # 0105
  • South Dakota
    • Rapid City, South Dakota, United States, 57701
      • Site # 0122
  • Texas
    • Austin, Texas, United States, 78723
      • Site # 1047

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

A patient will be eligible for study participation if they meet all of the following criteria:

1. Has participated in a Milestone Pharmaceuticals Inc. clinical research trial of etripamil NS for the treatment of PSVT (NODE-301 Part1, RAPID (NODE-301 Part 2), NODE-302, or NODE-303.
2. Has signed the MSP-2017-1278 written informed consent;

3. Women of childbearing potential who are sexually active with a male partner who is not surgically sterile (i.e., vasectomy) must be willing to use at least 1 form of highly effective contraception from the time of signed informed consent until 7 days after the last administration of etripamil NS and must be willing to discontinue from the study should they become or plan to become pregnant.

   The following categories define females who are not considered to be of childbearing potential:

   • Postmenopausal females, defined as having amenorrhea for at least 12 months without an alternative medical cause; or

   • Premenopausal females with 1 of the following:

     1. Documented hysterectomy; or
     2. Documented bilateral salpingectomy; or
     3. Documented bilateral oophorectomy; or

   All females who do not meet at least one of the above criteria are considered to be of childbearing potential

4. Willing and able to comply with Investigator instructions on etripamil NS use and study requirements.

Exclusion Criteria:

A patient will be excluded from the study if they meet any of the following criteria:

1. History of allergic reaction to verapamil, etripamil, or any of the investigational medical components;
2. Current chronic therapy with digoxin, or any Class I or III antiarrhythmic drug. Patients may be eligible if these drugs are stopped at least five half-lives before enrollment. The only exception is oral amiodarone which must be stopped 30 days before enrollment;
3. History of ventricular pre-excitation, e.g., delta waves, Wolff-Parkinson-White syndrome;
4. History of a second- or third-degree atrioventricular block;
5. History of sick sinus syndrome and marked bradycardia (≤40 beats/minute);
6. History or evidence of severe ventricular arrhythmia (e.g. torsades de points, ventricular fibrillation, or sustained ventricular tachycardia)
7. Symptoms of congestive heart failure New York Heart Association Class II to IV;
8. Significant physical or psychiatric condition including alcoholism or drug abuse, which, in the opinion of the Investigator, could jeopardize the safety of the patient, or impede the patient's capacity to follow the study requirements;
9. Syncope due to an arrhythmic etiology or unexplained syncope during or after participation in an etripamil clinical research trial;
10. Is pregnant, breastfeeding, or is planning to become pregnant during the study;
11. History of acute coronary syndrome (without successful revascularization) or stroke within 6 months of enrollment;
12. Evidence of symptoms of hypotension within 24 hours following previous administration of etripamil, per Investigator's opinion.
13. Has experienced a significant safety issue related to study drug administration during participation in a previous etripamil study for PSVT, per the Investigator's opinion.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Etripamil NS 70 mg; Self- administration of a dose of 70 mg of etripamil. Patients will be provided with a maximum of 4 pre-filled devices at a time. If the symptoms of PSVT persist 10 minutes after the first dose of etripamil NS 70 mg, a second dose of etripamil NS 70 mg can be self-administered by the patient. A second dose of etripamil NS 70 mg should be taken not earlier than 10, and not later than 15 minutes after the first dose.

Drug: Etripamil NS 70 mg; Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.; Device: Aptar Pharma Nasal Spray Bidose System; Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The safety of self-administered etripamil Nasal Spray (NS) for treatment of episodes of PSVT outside of the clinical setting as assessed by patient-reported adverse events.	Up to 3 years

Collaborators and Investigators

• Sponsor: Milestone Pharmaceuticals Inc.

Study record dates

Study Major Dates

• Study Start (Actual): December 13, 2021
• Primary Completion (Actual): April 10, 2026
• Study Completion (Actual): April 10, 2026

Study Registration Dates

• First Submitted: April 23, 2021
• First Submitted That Met QC Criteria: June 28, 2021
• First Posted (Actual): July 7, 2021

Study Record Updates

• Last Update Posted (Actual): May 15, 2026
• Last Update Submitted That Met QC Criteria: May 13, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiac Conduction System Disease; Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Arrhythmias, Cardiac; Tachycardia; Pathological Conditions, Signs and Symptoms; Tachycardia, Ventricular; Calcium-Regulating Hormones and Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Membrane Transport Modulators; Calcium Channel Blockers; Etripamil
• Other Study ID Numbers: MSP-2017-1278

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No